Paula Alexandra Popovici

Dr. Paula Alexandra Popovici


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background/Objectives: Type 2 diabetes mellitus (T2DM) is characterized by overlapping cardiovascular, renal, metabolic, and hepatic-risk abnormalities. We characterized this integrated phenotype, examined SCORE2-Diabetes gradients, and assessed whether routinely available variables could classify established atherosclerotic cardiovascular disease (ASCVD). Methods: This cross-sectional study included 232 consecutive adults with T2DM. SCORE2-Diabetes tertiles in the full cohort were analyzed descriptively, and a sensitivity analysis was restricted to participants aged 40–69 years without established ASCVD or severe target-organ damage. FIB-4 was recalculated from age, aspartate aminotransferase, alanine aminotransferase, and platelet count. Elastic-net logistic regression, random forest, and gradient boosting were evaluated using nested stratified five-fold cross-validation, with all preprocessing and hyperparameter tuning confined to the training folds. Results: Established ASCVD was present in 49 participants (21.1%), corresponding to 4.45 events per candidate predictor. The SCORE2-Diabetes-eligible sensitivity subgroup included 118 participants (50.9%); 72.9% were in the ≥20% 10-year-risk category. FIB-4 was available for 231 participants (median 1.26 [IQR 0.96–1.80]). Nested cross-validated ROC AUCs were 0.675 (95% CI 0.582–0.763) for elastic-net logistic regression, 0.670 (0.581–0.754) for random forest, and 0.674 (0.589–0.752) for gradient boosting; balanced accuracies were 65.4%, 62.8%, and 56.2%, respectively. Conclusions: The cohort had a high and heterogeneous cardio–renal–metabolic burden. SCORE2-Diabetes findings from the full cohort are descriptive because the score is not intended for patients with established ASCVD or severe target-organ damage. The machine-learning models showed only modest, internally validated discrimination and are not suitable for clinical deployment without larger prospective cohorts and external validation.

12 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
CCCorina Cinezan
Corina Cinezan
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Accurate scoring is essential when patient-reported self-management instruments are related to biochemical outcomes. The principal contribution of this study was to reconstruct and audit Diabetes Self-Management Questionnaire (DSMQ) scores from item-level data before reassessing their cross-sectional association with glycemic control. Methods: We performed a cross-sectional secondary analysis of a clinical database of adults with type 2 diabetes. One non-patient header row was removed. Because 12 observation-sheet identifiers occurred twice and visit dates were unavailable, all 24 records carrying repeated identifiers were excluded from the prespecified primary analysis, leaving 238 records. Negatively keyed DSMQ items were reverse-scored, and total and subscale scores were transformed to a 0–10 scale according to the original algorithm. Associations with HbA1c were assessed using Spearman correlation, exploratory ROC analysis, and multivariable linear regression with HC3 robust standard errors. Results: HbA1c was available for 237 records; mean age was 64.18 years (SD 11.14), 56.1% of records with valid sex coding were female, and mean HbA1c was 7.81% (SD 1.94). The corrected DSMQ total score was 5.19 (SD 2.36). DSMQ total score correlated inversely with HbA1c (ρ = −0.467, bootstrap 95% CI −0.572 to −0.350; p < 0.001). In the adjusted model (n = 236), each one-point higher DSMQ total score was associated with a 0.254 percentage-point lower HbA1c (regression coefficient = −0.254, 95% CI −0.344 to −0.163; p < 0.001). Sensitivity analyses using all records or first/last repeated-record rules produced similar estimates. Conclusions: Correctly scored DSMQ results showed a moderate, independent cross-sectional association with HbA1c. The corrected analysis did not demonstrate excellent discrimination, and the cross-sectional data cannot support causal or predictive claims. Prospective studies with verified unique participants and clearly documented data provenance are needed.

2 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
LMLenuta Ioana Moga
Lenuta Ioana Moga
TMTitus David Moga
Titus David Moga
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Baseline HbA1c is expected to dominate prediction of subsequent HbA1c status; therefore, the clinically relevant question is whether additional routinely available variables provide reproducible incremental value. Methods: This retrospective longitudinal study used 809 records from adults with type 2 diabetes receiving routine outpatient care. Six-month HbA1c was available for 808 participants. The primary outcome was six-month glycemic status (HbA1c < 7.0%). An HbA1c-only benchmark and three fixed blockwise logistic models were compared in the same complete-case cohort (n = 806). Internal validation used 1000 bootstrap resamples and reported optimism-corrected AUC, Brier score, calibration intercept, and calibration slope. Correlations, variance inflation factors (VIFs), nonlinear effects, decision-curve analysis, and a sensitivity analysis restricted to baseline HbA1c ≥ 7.0% were evaluated. Results: At baseline, 215 participants had HbA1c < 7.0%; 179 maintained this status, 206 newly reached <7.0%, 36 moved above the threshold, and 387 remained ≥7.0%. In complete cases, the optimism-corrected AUC was 0.868 (95% CI 0.844–0.892) for HbA1c alone and 0.870 (95% CI 0.848–0.893) for the full model. The corrected AUC difference between the full and HbA1c-only models was 0.001 (95% CI of −0.011 to 0.011). For the full model, the corrected Brier score was 0.146, the calibration intercept was 0.001, and the calibration slope was 0.925. VIFs were low (maximum of 1.33), although the TyG coefficient reversed direction after adjustment and was not interpreted causally. In participants with baseline HbA1c ≥ 7.0% (n = 592 complete cases), corrected AUCs were 0.850 for HbA1c alone and 0.849 for the full model. Conclusions: Baseline HbA1c accounts for nearly all discriminative performance. Added biomarkers and baseline therapeutic classes provide little internally validated incremental value, and the model should not be used for treatment decisions before external validation and prospective evaluation of clinical impact.

21 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Lifestyle modification is central to type 2 diabetes mellitus (T2DM) management, but adherence is difficult to assess in routine care. We developed a pragmatic Lifestyle Compliance Index (LCI) from routinely collected behavioral variables and examined its cross-sectional associations with cardio-renal-metabolic measures. Objectives: To describe the LCI, compare outcomes across adherence categories, evaluate adjusted associations, and quantify incremental discrimination for prevalent metabolic and renal abnormalities. Methods: Adults with T2DM attending a specialized outpatient diabetes clinic in Romania were assessed using a standardized clinical questionnaire and routine laboratory data. The LCI combined seven binary behaviors and graded physical activity (0–2 points; theoretical range 0–9). Group comparisons, unadjusted bivariate and adjusted multivariable regressions, false discovery rate correction, and stratified five-fold cross-validated logistic models were used. Results: Among 232 participants, 231 had a complete LCI; low, moderate, and high adherence included 84 (36.4%), 94 (40.7%), and 53 (22.9%) participants, respectively. Higher LCI scores were associated with lower adiposity, HbA1c, TyG index, triglycerides, creatinine, and SCORE2-Diabetes risk and with higher eGFR. In models adjusted for age, sex, and diabetes duration, each LCI point was associated with lower odds of obesity (aOR 0.749), elevated TyG index (0.757), albuminuria (0.716), reduced eGFR (0.802), and HbA1c ≥ 7% (0.833). Adding LCI improved cross-validated discrimination most for albuminuria (AUC 0.482 to 0.642), obesity (0.489 to 0.619), and elevated TyG index (0.524 to 0.646). The baseline albuminuria AUC was below chance, and the extended AUC remained modest. Conclusions: In this cross-sectional sample, higher self-reported lifestyle adherence was associated with a more favorable cardio-renal-metabolic profile. The LCI should be considered exploratory until validated against objective measures and tested in larger prospective populations.

9 September 2026 in Diseases
Verified
Journal Article
Open access
PDF file
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
RBRoxana Brata
Roxana Brata
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Contemporary management of type 2 diabetes mellitus (T2DM) extends beyond glycemic control and requires comprehensive assessment of cardiovascular, renal, metabolic, and anthropometric factors. Nevertheless, clinical status is often summarized predominantly by glycated hemoglobin (HbA1c), potentially overlooking concurrent non-glycemic abnormalities. This study evaluated the prevalence and coexistence of cardiorenal-metabolic abnormalities among patients with HbA1c <7.0% at six months. Methods: This retrospective observational study included adults with T2DM routinely followed in a specialized outpatient diabetes clinic. The primary descriptive analysis included participants with HbA1c <7.0% at the six-month assessment (T1). Seven non-glycemic cardiorenal-metabolic domains were evaluated at T1: LDL cholesterol, HDL cholesterol, triglycerides, body mass index, blood pressure, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio. An unweighted descriptive count of domains outside study-defined analytical thresholds was calculated (range, 0–7). An exploratory Poisson regression model examined associations between selected baseline characteristics and the number of affected domains, excluding baseline variables that directly corresponded to components of the T1 count to minimize mathematical coupling. Results: Among 809 participants, 385 (47.6%) had HbA1c <7.0% at six months and were included in the primary descriptive analysis. Concurrent non-glycemic abnormalities were common, particularly for blood pressure, LDL cholesterol, triglycerides, body mass index, and HDL cholesterol. The median number of domains outside study-defined analytical thresholds was three (IQR 3–4), and only three participants (0.8%) had values within all seven thresholds. In the exploratory multivariable model, none of the evaluated demographic, glycemic, or treatment-related baseline characteristics was independently associated with the number of domains outside study-defined thresholds. Conclusions: HbA1c <7.0% at six months did not necessarily coincide with favorable values across other clinically relevant cardiovascular, metabolic, anthropometric, and kidney-related domains in patients with T2DM. The unweighted domain count provides a descriptive summary of concurrent non-glycemic abnormalities but should not be interpreted as a validated measure of risk, prognosis, or clinical risk stratification. These findings support comprehensive, individualized assessment beyond glycemic status alone.

19 September 2026 in Diseases
Verified
Journal Article
Open access
PDF file
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Diabetes self-management is essential for type 2 diabetes care, but cross-sectional associations may be distorted when questionnaire scores are incorrectly derived or converted into arbitrary categories. We evaluated clinical and sociodemographic correlates of the continuous Diabetes Self-Management Questionnaire (DSMQ) total score in a secondary analysis of an outpatient clinical database. Methods: The analysis included 262 adults with type 2 diabetes recruited between 1 November 2025 and 1 May 2026. DSMQ total and subscale scores were independently recalculated from the 16 item-level responses using the published scoring algorithm. The primary analysis retained the DSMQ score as a continuous outcome. The database provided a participant-level count of documented glucose measurements > 250 mg/dL. This operational count was not treated as a standardized clinical event or severity category; individual measurement timestamps, participant-specific observation duration, and the total number of glucose measurements were unavailable. Results: The recalculated DSMQ score was 5.26 ± 2.35 (median 5.10; interquartile range 3.12–7.08). Among 261 participants with an interpretable sex code, 144 (55.2%) were women. In univariable analyses, lower DSMQ scores were concurrently associated with longer diabetes duration, a higher recorded severe-hyperglycemia count, higher HbA1c, and higher fasting glucose. In the adjusted model (n = 261), the recorded severe-hyperglycemia count remained negatively associated with DSMQ score (adjusted coefficient −0.412 points per recorded episode; 95% confidence interval −0.621 to −0.203; p < 0.001). Individualized versus hospital-based education was not independently associated with the corrected score. A beta-regression sensitivity analysis produced a concordant direction of association (coefficient −0.152 on the logit mean scale; p < 0.001). The linear model explained 17.2% of observed variance (adjusted R2 = 0.136), with an optimism-corrected R2 of 0.099. Conclusions: The recorded severe-hyperglycemia count was a concurrent correlate of lower DSMQ score. Because the study is cross-sectional and glucose-measurement counts were preaggregated without observation-time or monitoring-frequency data, the findings do not establish temporal direction, causality, or individual-level clinical prediction. Item-level score verification and continuous-outcome analysis materially changed the interpretation of the dataset.